论文部分内容阅读
目的:观察重组人干扰素α-1b雾化吸入治疗小儿手足口病的疗效。方法:将手足口病患儿107例随机分为观察组53例和对照组54例,对照组给予常规治疗及利巴韦林静滴。观察组在对照组基础上增加重组人干扰素雾化吸入治疗,比较两组治疗效果。结果:观察组有效率92.5%,病程短;对照组70.4%。结论:重组人干扰素雾化吸入治疗小儿手足口病可明显提高其疗效,且病程短,不良反应少。
Objective: To observe the efficacy of recombinant human interferon α-1b aerosol inhalation in the treatment of hand-foot-mouth disease in children. Methods: A total of 107 children with HFMD were randomly divided into observation group (n = 53) and control group (n = 54). The control group was given routine treatment and ribavirin. The observation group was treated with recombinant human interferon nebulized inhalation on the basis of the control group, and the therapeutic effect was compared between the two groups. Results: The observation group had an effective rate of 92.5% with a short course of disease and 70.4% of the control group. Conclusion: Recombinant human interferon nebulized inhalation for the treatment of hand-foot-mouth disease in children can obviously improve the curative effect, and has short course of disease and few adverse reactions.